Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Role of Calcium-Phosphate Product and Bone-Associated Proteins on Vascular Calcification in Renal Failure

Open access
COZZOLINO, MARIO, DUSSO, ADRIANA S., SLATOPOLSKY, EDUARDO·2001·Journal of the American Society of Nephrology

Abstract

Cardiovascular events are the most frequent cause of death in patients with chronic renal failure (1,2). Heterotopic calcification of blood vessel walls occurs frequently with advanced age, atherosclerosis, and diabetes mellitus (3). In chronic renal failure, autopsy (4,5) and clinical investigations (6) have documented a higher prevalence of coronary plaques in dialyzed patients compared with the nonuremic population. The risk factors that contribute to the higher prevalence of atherosclerotic lesions in chronic renal failure include dyslipidemia, hyperhomocysteinemia, and hypertension (3). In addition, hyperphosphatemia and increased calcium-phosphate product are important contributors to vascular calcifications in patients with uremia (7). A new, noninvasive imaging technology, electron beam computed tomography, has demonstrated that both hyperphosphatemia and increased calcium-phosphate product cause a progressive increase in calcium deposition in the coronary arteries and mitral and aortic valves in patients with advanced renal failure (8). Hyperphosphatemia associates with ectopic calcifications, increased risk of calciphylaxis, and calcinosis (9,10). Figure 1 illustrates direct and indirect mechanisms for hyperphosphatemia to increase calcium-phosphate product. High levels of phosphate, due to phosphorus retention, worsen the secondary hyperparathyroidism commonly present in renal failure through direct and indirect mechanisms. High phosphate enhances parathyroid cell proliferation and parathyroid hormone (PTH) synthesis and secretion directly and indirectly through both a reduction in serum calcitriol and ionized calcium levels and a reduction of skeletal resistance to PTH. The resultant high PTH causes osteitis fibrosa and bone loss and therefore further increases in calcium-phosphate product (11,12). In addition to its effects on bone, high PTH, by elevating cytosolic calcium, could cause microcalcifications, as has been demonstrated in lung (13) and skin (14). Also, PTH impairment of lipid metabolism and immune cell function (15) could directly contribute to enhance cardiovascular calcification. The relative contribution of hyperphosphatemia, high calciumphosphate product, and secondary hyperparathyroidism to enhance vascular calcification, as well as the mechanisms involved, are incompletely understood.Figure 1.: Potential side effects of hyperphosphatemia in renal failure.In recent years, vascular calcification was shown to involve not a passive deposition of calcium-phosphate crystals on atherosclerotic vessels but an active process in which vascular cells elicit osteoblastic functions (16). Furthermore, there is a paradoxical coincidence of vascular mineralization with bone loss in human and animal models, which suggests that the same factors that induce high-turnover bone disease in renal failure could also mediate vascular calcification. This review presents the emerging understanding of the mechanisms by which hyperphosphatemia and elevated Ca × P product affect vascular calcification. In addition, we present the biologic interactions and functional parallels between bone and vascular tissues in bone-associated proteins and PTH-related peptide (PTH-rP). Phosphate Regulation of Vascular Calcification Hyperphosphatemia associates with prosthetic cardiac valve calcification and osteocalcin deposition in experimental animals with normal renal function (17). Recent studies have demonstrated phosphate regulation of vascular calcification and provided some insights into the mechanisms for phosphate induction of metastatic calcifications. In vivo studies by Kuro-o et al. (18), in the KLOTHO-gene mutant mice with a phenotype that resembles human aging, demonstrated that, in the presence of normal serum creatinine, albumin, cholesterol, and triglyceride levels and with only a mild increase in serum calcium levels (from 9.5 to 10.6 mg/dl), a two-fold increase in serum phosphate levels resulted in increased calcium-phosphate product as well as the development of vascular calcifications and osteoporosis that were clearly unrelated to malnutrition, abnormal lipid metabolism, or chronic renal failure. Because hyperphosphatemia was the main determinant of the increased Ca × P product, Jono et al. (19) assessed the contribution of hyperphosphatemia per se on vascular calcification. High phosphorus levels in the incubation media (2 mmol/L P) enhanced calcification in human aortic smoothmuscle cells. Phosphate-containing mineral deposition, assessed by von Kossa staining and light microscopy, was predominant in the extracellular regions of the cultures, with the greatest accumulation at sites of cell multilayering (19). Furthermore, these studies demonstrated that high phosphate directly increases human aortic smooth-muscle cells calcification and the expression of the osteoblast-specific genes Osf2/Cbfa-1 and osteocalcin (19) (Figure 2). Both effects of high P are mediated by the sodium-phosphate cotranspor

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v12112511

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 188

Metadata

Authors
COZZOLINO, M., DUSSO, A. S., & SLATOPOLSKY, E.
Venue
Journal of the American Society of Nephrology
Published
2001-11
Volume
12
Issue
11
Pages
2511-2516
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2143600593
Cited by
188
References
1
FWCI
4.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Calcium-Phosphate Product and Bone-Associated Proteins on Vascular Calcification in Renal Failure. https://app.cochat.ai/papers/10.1681/asn.v12112511
The paper
COZZOLINO, M., DUSSO, A. S., & SLATOPOLSKY, E. (2001). Role of Calcium-Phosphate Product and Bone-Associated Proteins on Vascular Calcification in Renal Failure. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v12112511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.